Related Experiment Video
Updated: Jun 8, 2026

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
Published on: February 23, 2024
Recent advances in the development of novel mucosal adjuvants and antigen delivery systems
Wangxue Chen1, Girishchandra B Patel, Hongbin Yan
1Institute for Biological Sciences, National Research Council Canada, Ottawa, ON, Canada; Department of Biology, Brock University, St. Catharines, ON, Canada. Wangxue.Chen@nrc-cnrc.gc.ca.
Abstract:
Mucosal infections and associated diseases remain a major socio-economic burden to society. Since parenteral immunizations fail to induce efficient protective immunity at mucosal surfaces, mucosal immunization is a logical approach to prevent and treat mucosally-initiated infections. All currently approved human mucosal vaccines are based on attenuated or killed whole pathogen cells but this strategy does pose safety concerns. Therefore, substantial effort is being invested to develop safe and effective mucosal adjuvants and delivery systems for mucosal vaccines. Encouragingly, some of these have progressed to advanced preclinical and clinical studies. This review discusses the promising preclinical research and the potential applications of several novel mucosal adjuvants and delivery systems: an archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) system, 3',5'-cyclic diguanylic acid (c-di-GMP) and detoxified bacterial AB(5) toxins. The potential and challenges in targeting M cells for mucosal vaccination are also discussed.
More Related Videos
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Oral Drug Delivery Systems: Introduction
Vaccinations
Vaccines
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

